Clinical Trial: Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07898709) titled 'Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI' on Oct. 16.

Brief Summary: Study Background & Purpose:

The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI). It leads to poor myocardial perfusion despite successful opening of the culprit coronary artery. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardioprotective mechanisms beyond glucose control.

Objective:

This randomized controlled trial aims to evaluate the effectiveness and safety of administer...